Pet amiloide en la esclerosis múltiple

  1. Pytel, Vanesa
unter der Leitung von:
  1. Jorge Matías-Guiu Guía Doktorvater/Doktormutter
  2. Jordi A. Matías-Guiu Doktorvater/Doktormutter
  3. María Nieves Cabrera Martín Doktorvater/Doktormutter

Universität der Verteidigung: Universidad Complutense de Madrid

Fecha de defensa: 30 von September von 2019

Gericht:
  1. José Luis Carreras Delgado Präsident/in
  2. Francisco Grandas Pérez Sekretär/in
  3. Alfredo Rodríguez-Antigüedad Zarranz Vocal
  4. Mª Rosario Blasco Quílez Vocal
  5. Julián Benito León Vocal

Art: Dissertation

Zusammenfassung

Multiple sclerosis (MS) is the most common demyelinating disease and the main cause of non-traumatic neurological disability in young adults. It is a clinically heterogeneous disease, including motor, cognitive and fatigue symptoms. This is the result of a combination of the main pathophysiological processes involved: inflammation, demyelination, axonal damage and neurodegeneration. In recent years, various disease-modifying therapies have been developed, aimed at acting on the immune system, with an anti-inflammatory effect that prevents relapses and slows the progression of disability...